You are here

Article Text

Article menu

Download PDFPDF

Review
Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice
  1. Pierre Miossec
  1. Immunogenomics and Inflammation Research Unit EA 4130, Department of Immunology and Rheumatology, University of Lyon, Lyon, France
  1. Correspondence to Professor Pierre Miossec; pierre.miossec{at}univ-lyon1.fr

Abstract

Interleukin-17 (IL-17A) is a cytokine critical for the acute defence against extracellular bacterial and fungal infections. Excess production during chronic inflammation has been associated with many inflammatory and autoimmune disorders. The present review describes the key molecules of the IL-17 pathway, which are or could be targeted for treatment. Since targeting of IL-17A may affect defence mechanisms, the pathogenesis of such possible adverse events is analysed. Then the contributions of IL-17 to bone changes in various forms of arthritis are discussed. Finally, the results of current inhibitors of the IL-17 pathway in clinical trials are detailed. IL-17A inhibition has been first registered for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Other therapeutic options are now tested in a long list of diseases.

  • Cytokines
  • Inflammation
  • Treatment

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/rmdopen-2016-000284

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding Part of the work is supported by the IHU prometteur OPERA. PM is a senior member of, and supported by, the Institut Universitaire de France.

    • Competing interests PM holds a patent on the determination of bioactive IL-17.

    • Provenance and peer review Commissioned; externally peer reviewed.

    • Data sharing statement No additional data are available.